Online inquiry

IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ10093MR)

This product GTTS-WQ10093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Gastric Cancer research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_000245.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	4233
UniProt ID	P08581

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10093MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15262MR	IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	Tarvacin ch3G4
GTTS-WQ14851MR	IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	SGN-CD33A
GTTS-WQ8885MR	IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	IFN-alpha-REC
GTTS-WQ12515MR	IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	NPVPDR001
GTTS-WQ12311MR	IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MT203
GTTS-WQ14652MR	IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	SC-003 mAb
GTTS-WQ7398MR	IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	GA101
GTTS-WQ10223MR	IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	LFB-R593

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST